Intellia Therapeutics, Inc.
$10.00+$0.48 (+5.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $2.1B
- Revenue
- $67.7M
- Net margin
- -609.9%
- ROCE
- -65.7%
Price chart
Technical chartScreen technicals →+24.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -15.5%
- 3M
- -19.6%
- 6M
- -18.4%
- 1Y
- +24.4%
- 5Y
- -92.3%
52-week range
Day change +$0.48 (+5.0%) from $9.52 to $10.00 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in NTLA, bought on each weekday since 2021.
News & filings
What Intellia Therapeutics filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 413 million US dollars in fiscal 2025.
Strengths (1)
- Revenue grew 16.9% in fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.
Read moreShow less
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 116.3M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $2.1B
- P/B
- 3.1x
- EV / Sales
- 25.2x
- P/S
- 30.5x
- 52-week high
- $17.84
- 52-week low
- $8.04
Profitability
- Operating margin
- -651.7%
- Net margin
- -609.9%
- EBITDA margin
- -628.2%
- ROE
- -61.5%
- ROCE
- -65.7%
- ROIC
- -57.2%
- ROA
- -49.0%
- Asset turnover
- 0.08
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $67.7M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 16.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 9.1%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -20.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$395.9M
Solvency
- Current ratio
- 5.08
- Debt / Equity
- 0.14
- Debt / Assets
- 0.11
- CFO / Net profit
- 0.96
- Cash / Market cap
- 21.8%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $67.7M |
| Gross profit | $67.7M |
| Operating expenses | $508.7M |
| Research and development | $388.9M |
| Selling, general and administrative | $119.8M |
| Operating income | -$441.0M |
| Interest and other | $28.3M |
| Pretax income | -$412.7M |
| Tax and other | $0.00 |
| Net income | -$412.7M |
Revenue and net profit
Revenue grew 16.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $52.1M | -$474.2M |
| FY2023 | $36.3M | -$481.2M |
| FY2024 | $57.9M | -$519.0M |
| FY2025 | $67.7M | -$412.7M |
Cash flows
FY2025: -$394.7M from operations, -$395.9M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$333.3M | -$391.7M |
| FY2023 | -$394.1M | -$408.1M |
| FY2024 | -$348.9M | -$354.7M |
| FY2025 | -$394.7M | -$395.9M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $67.7M+16.9%1Y
- EBITDA
- -$425.1M
- Net profit
- -$412.7M
- Cash from operations
- -$394.7M
- Free cash flow
- -$395.9M
- Revenue CAGR, 3Y
- 9.1%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $67.7M | -$425.1M | -$412.7M | -$395.9M | -61.5% | +16.9% | -20.5% |
Monthly returns
Month-by-month returns of NTLA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $842.1M |
| Current assets | $527.7M |
| Non-current assets | $314.4M |
| Liabilities | $170.7M |
| Current liabilities | $103.9M |
| Non-current liabilities | $66.8M |
| Equity | $671.4M |
| Paid-in capital | $3.3B |
| Retained earnings | -$2.6B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; NTLA highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Kodiak Sciences Inc., Trevi Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc.NTLAthis company | $2.1B | — | 3.1x | -61.5% | — |
| Kodiak Sciences Inc.KOD | $2.1B | — | 13.6x | -146.1% | — |
| Aurinia Pharmaceuticals Inc.AUPH | $2.1B | 7.3x | 3.6x | 49.4% | 15.2x |
| Clover Health Investments, Corp.CLOV | $2.1B | -24.6x | 6.8x | -27.7% | — |
| NovoCure LimitedNVCR | $2.1B | — | 6.1x | -40.0% | — |
| Recursion Pharmaceuticals, Inc.RXRX | $2.0B | -3.1x | 1.8x | -57.0% | -2.4x |
| Progyny, Inc.PGNY | $2.0B | 34.1x | 3.9x | 11.3% | 21.2x |
| Omnicell, Inc.OMCL | $2.0B | 967.3x | 1.6x | 0.2% | 21.5x |
| Trevi Therapeutics, Inc.TRVI | $2.0B | -46.3x | 10.8x | -23.3% | -45.9x |
| Peer median | — | 2.1x | 5.0x | -25.5% | 15.2x |
Year-to-date ROI
NTLA since 1 January, against earlier years.
Historical volatility
NTLA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -879.0% |
| FY2023 | -1420.3% |
| FY2024 | -923.0% |
| FY2025 | -651.7% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $67.7M |
| Operating expensesOperating Expense | $508.7M |
| Research and developmentResearch And Development | $388.9M |
| Selling, general and administrativeSelling General And Administration | $119.8M |
| Total expensesTotal Expenses | $508.7M |
| Operating incomeOperating Income | -$441.0M |
| Interest and other | |
| Pretax incomePretax Income | -$412.7M |
| Tax | |
| Net incomeNet Income | -$412.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $842.1M |
| Current assetsCurrent Assets | $527.7M |
| Non-current assetsTotal Non Current Assets | $314.4M |
| LiabilitiesTotal Liabilities Net Minority Interest | $170.7M |
| Current liabilitiesCurrent Liabilities | $103.9M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $66.8M |
| EquityTotal Equity Gross Minority Interest | $671.4M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$394.7M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$394.7M |
| Net income, continuing operationsNet Income From Continuing Operations | -$412.7M |
| Depreciation and amortisationDepreciation And Amortization | $15.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $15.9M |
| Depreciation | $15.9M |
| Amortization of securitiesAmortization Of Securities | -$5.9M |
| Stock-based compensationStock Based Compensation | $80.2M |
| Operating gains and lossesOperating Gains Losses | $530.0k |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $530.0k |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | $900.0k |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $0.00 |
| Change in working capitalChange In Working Capital | -$73.8M |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | $228.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $228.0M |
| Capital expenditureCapital Expenditure | -$1.1M |
| Purchase of PP&EPurchase Of PPE | -$1.1M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$1.1M |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | -$322.5M |
| Sale of investmentsSale Of Investment | $551.7M |
| Net investment purchases and salesNet Investment Purchase And Sale | $229.2M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Financing cash flowFinancing Cash Flow | $131.5M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $131.5M |
| Shares issuedIssuance Of Capital Stock | $128.2M |
| Common stock issuedCommon Stock Issuance | $128.2M |
| Net common stock issuedNet Common Stock Issuance | $128.2M |
| Stock options exercisedProceeds From Stock Option Exercised | $3.3M |
| Change in cashChanges In Cash | -$35.2M |
| Cash at the start of the yearBeginning Cash Position | $202.8M |
| Cash at the end of the yearEnd Cash Position | $167.6M |
| Free cash flowFree Cash Flow | -$395.9M |
Learn while you research
Academy chapters picked for Intellia Therapeutics, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read